Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Volume 342, Issue 1, Pages (January 2014)
Advertisements

Molecular Therapy - Nucleic Acids
Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.
M. Fu, G. Huang, Z. Zhang, J. Liu, Z. Zhang, Z. Huang, B. Yu, F. Meng 
Long Noncoding RNA HOTAIR Controls Cell Cycle by Functioning as a Competing Endogenous RNA in Esophageal Squamous Cell Carcinoma  Kewei Ren, Yahua Li,
Volume 145, Issue 2, Pages (August 2013)
DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer  Yi-Chieh Yang, MS, Yen-An Tang,
High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer  Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Therapeutic Suppression of miR-4261 Attenuates Colorectal Cancer by Targeting MCC  Guanming Jiao, Qi Huang, Muren Hu, Xuchun Liang, Fuchen Li, Chunling.
Histone Demethylase LSD2 Acts as an E3 Ubiquitin Ligase and Inhibits Cancer Cell Growth through Promoting Proteasomal Degradation of OGT  Yi Yang, Xiaotong.
Volume 21, Issue 5, Pages (October 2017)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 8, Pages (August 2017)
Brachyury-YAP Regulatory Axis Drives Stemness and Growth in Cancer
Kobe C. Yuen, Baoshan Xu, Ian D. Krantz, Jennifer L. Gerton 
Volume 21, Issue 6, Pages (June 2013)
Molecular Therapy - Nucleic Acids
Uc.454 Inhibited Growth by Targeting Heat Shock Protein Family A Member 12B in Non- Small-Cell Lung Cancer  Jun Zhou, Chenghai Wang, Weijuan Gong, Yandan.
Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer  Meng Zhou, Long Hu, Zicheng.
Molecular Therapy - Nucleic Acids
Volume 145, Issue 2, Pages (August 2013)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 3, Pages (March 2017)
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2  Ji-guang Zhang,
Volume 4, Issue 3, Pages (August 2013)
Volume 10, Issue 8, Pages (March 2015)
Volume 25, Issue 9, Pages (September 2017)
Volume 142, Issue 7, Pages e2 (June 2012)
Molecular Therapy - Nucleic Acids
TGFβ/SMAD/microRNA-486-3p Signaling Axis Mediates Keratin 17 Expression and Keratinocyte Hyperproliferation in Psoriasis  Man Jiang, Zhongbin Sun, Erle.
MiR-135b Stimulates Osteosarcoma Recurrence and Lung Metastasis via Notch and Wnt/β-Catenin Signaling  Hua Jin, Song Luo, Yun Wang, Chang Liu, Zhenghao.
Volume 5, Issue 4, Pages e4 (October 2017)
BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells  Duc-Hiep Bach,
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Molecular Therapy - Nucleic Acids
Wei Jiang, Yuting Liu, Rui Liu, Kun Zhang, Yi Zhang  Cell Reports 
Volume 9, Issue 5, Pages (November 2017)
Lu Zheng, Nan You, Xiaobing Huang, Huiying Gu, Ke Wu, Na Mi, Jing Li 
Kun-Peng Zhu, Xiao-Long Ma, Chun-Lin Zhang  Molecular Therapy 
Volume 16, Issue 10, Pages (September 2016)
Volume 19, Issue 8, Pages (August 2011)
Volume 5, Issue 4, Pages e4 (October 2017)
ADAR Regulates RNA Editing, Transcript Stability, and Gene Expression
Molecular Therapy - Nucleic Acids
Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System  Haoran Xin, Mingxing Lei, Zhihui Zhang, Jie Li, Hao Zhang,
Figure 1. RSPO3 expression is upregulated in bladder cancer
Molecular Therapy - Nucleic Acids
Volume 17, Issue 2, Pages (February 2009)
Volume 36, Issue 2, Pages (October 2009)
Volume 25, Issue 4, Pages (April 2017)
Shrimp miR-34 from Shrimp Stress Response to Virus Infection Suppresses Tumorigenesis of Breast Cancer  Yalei Cui, Xiaoyuan Yang, Xiaobo Zhang  Molecular.
Molecular Therapy - Nucleic Acids
Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3  Jiaxin Lin, Xin Tan,
Volume 26, Issue 11, Pages (November 2018)
Volume 15, Issue 12, Pages (June 2016)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Volume 6, Issue 3, Pages (March 2016)
MiR-409 Inhibits Human Non-Small-Cell Lung Cancer Progression by Directly Targeting SPIN1  Qi Song, Quanbo Ji, Jingbo Xiao, Fang Li, Lingxiong Wang, Yin.
Molecular Therapy - Nucleic Acids
The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2  Cheng-Cao Sun, Ling Zhang, Guang.
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Hui Deng, Jing Liu, Yu Deng, Gangwen Han, Yiqun G. Shellman, Steven E
Molecular Therapy - Nucleic Acids
Volume 22, Issue 9, Pages (September 2014)
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Molecular Therapy - Nucleic Acids
Circular RNA Transcriptomic Analysis of Primary Human Brain Microvascular Endothelial Cells Infected with Meningitic Escherichia coli  Ruicheng Yang,
Molecular Therapy - Nucleic Acids
Presentation transcript:

Molecular Therapy - Nucleic Acids Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma  Rui Chen, Wenjia Xia, Siwei Wang, Youtao Xu, Zhifei Ma, Weizhang Xu, Erbao Zhang, Jie Wang, Tian Fang, Quan’an Zhang, Gaochao Dong, William Chi-shing Cho, Patrick C. Ma, Giovanni Brandi, Simona Tavolari, Peter Ujhazy, Giulio Metro, Helmut H. Popper, Rong Yin, Mantang Qiu, Lin Xu  Molecular Therapy - Nucleic Acids  Volume 16, Pages 543-553 (June 2019) DOI: 10.1016/j.omtn.2019.04.004 Copyright © 2019 The Authors Terms and Conditions

Figure 1 Screening Early-Stage-Specific lncRNAs in LUAD The flowchart of WGCNAs and lncRNAs screening (A). 7,320 differentially expressed genes screened from the TCGA LUAD project (B). Hierarchical clustering of 508 LUAD cancer tissue samples based on 7,320 differentially expressed genes (C). 12 significant co-expression gene modules across all 508 sampling sets were demonstrated with WGCNA TOMplot. Identified co-expression modules were represented by color classifiers (gray is assigned to genes that are not part of any module) (D). PCC between the MEs and TNM stages. A positive value indicates that the genes within a particular co-expression module increase as the variable increases, and each PCC value is accompanied by the corresponding p value in brackets (left panel). The heatmap of all 541 differentially expressed lncRNAs in GSE19804 (top panel); screened 59 lncRNAs were subjected to the correlation heatmap (bottom panel) (E). Molecular Therapy - Nucleic Acids 2019 16, 543-553DOI: (10.1016/j.omtn.2019.04.004) Copyright © 2019 The Authors Terms and Conditions

Figure 2 High Expression Indicates Poor Survival of LUAD GSEA results showed that SBF2-AS1 was positively correlated with a gene set of poor survival (p = 0.006; A) and negatively correlated with a gene set of good survival (p = 0.074; B). High expression of SBF2-AS1 was associated with shorter overall survival time in LUAD, especially in T1-stage LUAD, but not in LUSC (C). TCGA data also suggest that high SBF2-AS1 expression associates with shorter survival time in LUAD but not in LUSC (D). NES, normalized enrichment score. Molecular Therapy - Nucleic Acids 2019 16, 543-553DOI: (10.1016/j.omtn.2019.04.004) Copyright © 2019 The Authors Terms and Conditions

Figure 3 SBF2-AS1 Promotes Proliferation of LUAD Cells The deregulated genes after the silence of SBF2-AS1 were significantly enriched in biological processes of the cell cycle (A). The cell cycle was arrested at G1 phase in A549 cells upon SBF2-AS1 knockdown (B). Cyclin D1 and P21 expression after silence and overexpression of SBF2-AS1 (C). Knockdown of SBF2-AS1 inhibited A549 cell proliferation but overexpression of SBF2-AS1 increased cell proliferation activity, as revealed by CCK-8 (D), EdU (E), and colony formation (F) assays. *p < 0.05; **p < 0.01. Error bars stand for mean and SE. Molecular Therapy - Nucleic Acids 2019 16, 543-553DOI: (10.1016/j.omtn.2019.04.004) Copyright © 2019 The Authors Terms and Conditions

Figure 4 SBF2-AS1 Binds with miR-338-3p and miR-362-3p SBF2-AS1 is located in both cytoplasm and nucleus in LUAD cells (A). PAR-CLIP-seq data suggested that SBF2-AS1 could bind with miR-338-3p and miR-362-3p (B). RIP assay using antibody specifically targeting Ago2 showed that SBF2-AS1 could bind with Ago2 protein in A549 cells (C). Biotin-coupled miRNA pull-down assay showed that SBF2-AS1 was significantly enriched by miR-338-3p and miR-362-3p (D). Compared with control RNA, overexpression of miR-338-3p (E) or miR-362-3p (F) did not alter SBF2-AS1 expression. E2F1 is the target of miR-338-3p and miR-362-3p. Venn plot showed that 8 cell-cycle-related genes were overlapped with predicted targets of miR-338-3p and miR-362-3p (G). Blue circle: cell-cycle-related genes that were selected from downregulated genes upon SBF2-AS1 knockdown; yellow circle: predicted targets of miR-338-3p; green circle: predicted targets of miR-362-3p. E2F1 was mostly downregulated upon SBF2-AS1 knockdown (H). Biotin-labeled miRNA pull-down assay showed that miR-338-3p and miR-362-3p could bind with E2F1 (I). In a dual-luciferase reporter assay, luciferase activity was inhibited by miR-338-3p (J) and miR-362-3p (K), but the inhibition was abolished when the binding sites of miR-338-3p (J) and miR-362-3p (K) were mutated, respectively. E2F1 mRNA expression level decreased upon ectopic expression of miR-338-3p (L) or miR-362-3p (M). *p < 0.05; **p < 0.01; N.S, no statistical significance. Error bars stand for mean and SE. Molecular Therapy - Nucleic Acids 2019 16, 543-553DOI: (10.1016/j.omtn.2019.04.004) Copyright © 2019 The Authors Terms and Conditions

Figure 5 SBF2-AS1-miR-338-3p/362-3p-E2F1 Axis Promotes LUAD Tumorigenesis E2F1 protein level decreased as SBF2-AS1 was knocked down and increased as SBF2-AS1 was overexpressed (A). Expression of SBF2-AS1 and expression of E2F1 were positively correlated in LUAD tissues (p = 0.0001, R2 = 0.772) (B). E2F1 protein level was decreased by miR-338-3p and miR-362-3p and could be restored by SBF2-AS2, but after mutation of miR-338-3p (C) or miR-362-3p (D) binding sites, the SBF2-AS1-MUT could not restore E2F1 expression (C and D). Overexpression of SBF2-AS1 increased A549 cell proliferation activity, while the increase could be partially reversed by both miR-338-3p and miR-362-3p, and co-administration of miR-338-3p and miR-362-3p completely abolished the promoting effect driven by SBF2-AS1; colony formation assay was used in (E), and EdU assay was used in (F). *p < 0.05, **p < 0.01; N.S, no statistical significance. Error bars stand for mean and SE. Molecular Therapy - Nucleic Acids 2019 16, 543-553DOI: (10.1016/j.omtn.2019.04.004) Copyright © 2019 The Authors Terms and Conditions

Figure 6 SBF2-AS1 Promotes LUAD Tumorigenesis In Vivo SBF2-AS1 overexpression promoted lung cancer growth in a nude-mouse xenograft model; however, when the binding sites of miR-338-3p and miR-362-3p were both mutated, SBF2-AS1-MUT failed to promote growth of lung cancer (A). H&E staining and IHC staining of xenograft tumor tissues (B). The mechanic diagram of SBF2-AS1 promoting LUAD tumorigenesis (C). *p < 0.05, N.S., no statistical significance, and error bars stand for mean and SE. Molecular Therapy - Nucleic Acids 2019 16, 543-553DOI: (10.1016/j.omtn.2019.04.004) Copyright © 2019 The Authors Terms and Conditions